Costs and Cost-Effectiveness of Allogeneic Stem Cell Transplantation in Children Are Predictable

Biology of Blood and Marrow Transplantation

Volumn 18, Issue 10, 2012, Pages 1533-1539

  Matthes Martin, Susanne ^a   Pötschger, Ulrike ^a   Barr, Ronald ^b   Martin, Manuel ^a   Boztug, Heidrun ^a   Klingebiel, Thomas ^c   Attarbaschi, Andishe ^a   Eibler, Werner ^a   Mann, Georg ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b MCMASTER UNIVERSITY   (Canada)

^c GOETHE UNIVERSITY   (Germany)

Author keywords

Cost calculation in pediatric stem cell transplantation; Costs per life year gained

Indexed keywords

ADOLESCENT; ADULT; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; CHILD; COHORT ANALYSIS; COST EFFECTIVENESS ANALYSIS; DONOR; HUMAN; INFANT; MAJOR CLINICAL STUDY; OVERALL SURVIVAL; PEDIATRICS; PRESCHOOL CHILD; SCHOOL CHILD; SURGICAL MORTALITY;

ADOLESCENT; AGE FACTORS; CHILD; CHILD, PRESCHOOL; COST-BENEFIT ANALYSIS; FEMALE; HEMATOLOGIC NEOPLASMS; HUMANS; INFANT; LONGITUDINAL STUDIES; QUALITY OF LIFE; RESEARCH DESIGN; RISK ASSESSMENT; SIBLINGS; STEM CELL TRANSPLANTATION; SURVIVAL ANALYSIS; TRANSPLANTATION, HOMOLOGOUS; UNRELATED DONORS; YOUNG ADULT;

EID: 84866168665     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2012.04.002     Document Type: Article

References (40)

1. Meropol N.J., Schrag D., Smith T.J., et al. American Society of Clinical Oncology guidance statement: the cost of cancer care. J Clin Oncol 2009, 27:3868-3874.
2. Meropol N.J., Schulman K.A. Cost of cancer care: issues and implications. J Clin Oncol 2007, 25:180-186.
3. Barr R.D. Costs and consequences of stem cell transplantation in children. Pediatr Transplant 2003, 7(suppl 3):7-11.
4. Esperou H., Brunot A., Roudot-Thoraval F., et al. Predicting the costs of allogeneic sibling stem-cell transplantation: results from a prospective, multicenter, French study. Transplantation 2004, 77:1854-1858.
5. Imataki O., Kamioka T., Fukuda T., et al. Cost and effectiveness of reduced-intensity and conventional allogeneic hematopoietic stem cell transplantation for acute myelogenous leukemia and myelodysplastic syndrome. Support Care Cancer 2010, 18:1565-1569.
6. Krejci M., Mayer J., Doubek M., et al. Clinical outcomes and direct hospital costs of reduced-intensity allogeneic transplantation in chronic myeloid leukemia. Bone Marrow Transplant 2006, 38:483-491.
7. Majhail N.S., Mothukuri J.M., Brunstein C.G., et al. Costs of hematopoietic cell transplantation: comparison of umbilical cord blood and matched related donor transplantation and the impact of posttransplant complications. Biol Blood Marrow Transplant 2009, 15:564-573.
8. Majhail N.S., Mothukuri J.M., Macmillan M.L., et al. Costs of pediatric allogeneic hematopoietic-cell transplantation. Pediatr Blood Cancer 2010, 54:138-143.
9. Barr R.D., Feeny D., Furlong W. Economic evaluation of treatments for cancer in childhood. Eur J Cancer 2004, 40:1335-1345.
10. Weinstein M.C., Siegel J.E., Gold M.R., et al. Recommendations of the Panel on Cost-Effectiveness in Health and Medicine. JAMA 1996, 276:1253-1258.
11. Fojo T., Grady C. How much is life worth: cetuximab, non-small cell lung cancer, and the $440 billion question. J Natl Cancer Inst 2009, 101:1044-1048.
12. Cohen J., Looney W. What is the value of oncology medicines?. Nat Biotechnol 2010, 28:1160-1163.
13. Campbell M.J., Machin D., Walters S.J. Medical Statistics: A Textbook for the Health Sciences 2007, Wiley-Interscience, Hoboken, NJ, 138, 181.
14. Huber P.J. Robust regression: asymptotics, conjectures and Monte Carlo. Ann Stat 1973, 1:799-821.
15. Matthes-Martin S., Pötschger U., Bergmann K., et al. Risk-adjusted outcome measurement in pediatric allogeneic stem cell transplantation. Biol Blood Marrow Transplant 2008, 14:335-343.
16. Sposto R. Cure model analysis in cancer: an application to data from the Children's Cancer Group. Stat Med 2002, 21:293-312.
17. Corbiere F., Joly P. A SAS macro for parametric and semiparametric mixture cure models. Comput Methods Programs Biomed 2007, 85:173-180.
18. Goldman J.M., Majhail N.S., Klein J.P., et al. Relapse and late mortality in 5-year survivors of myeloablative allogeneic hematopoietic cell transplantation for chronic myeloid leukemia in first chronic phase. J Clin Oncol 2010, 28:1888-1895.
19. Wingard J.R., Majhail N.S., Brazauskas R., et al. Long-term survival and late deaths after allogeneic hematopoietic cell transplantation. J Clin Oncol 2011, 29:2230-2239.
20. Matthes-Martin S., Lamche M., Ladenstein R., et al. Organ toxicity and quality of life after allogeneic bone marrow transplantation in pediatric patients: a single centre retrospective analysis. Bone Marrow Transplant 1999, 23:1049-1053.
21. Martin P.J., Counts G.W., Appelbaum F.R., et al. Life expectancy in patients surviving more than 5 years after hematopoietic cell transplantation. J Clin Oncol 2010, 28:1011-1016.
22. Nietfeld J.J., Pasquini M.C., Logan B.R., et al. Lifetime probabilities of hematopoietic stem cell transplantation in the US. Biol Blood Marrow Transplant 2008, 14:316-322.
23. Reismuller B., Attarbaschi A., Peters C., et al. Long-term outcome of initially homogenously treated and relapsed childhood acute lymphoblastic leukaemia in Austria: a population-based report of the Austrian Berlin-Frankfurt-Munster (BFM) Study Group. Br J Haematol 2009, 144:559-570.
24. Mishra V., Vaaler S., Brinch L. A prospective cost evaluation related to allogeneic haemopoietic stem cell transplantation including pretransplant procedures, transplantation and 1-year follow-up procedures. Bone Marrow Transplant 2001, 28:1111-1116.
25. Cordonnier C., Maury S., Esperou H., et al. Do minitransplants have minicosts? A cost comparison between myeloablative and nonmyeloablative allogeneic stem cell transplant in patients with acute myeloid leukemia. Bone Marrow Transplant 2005, 36:649-654.
26. Svahn B.M., Alvin O., Ringden O., et al. Costs of allogeneic hematopoietic stem cell transplantation. Transplantation 2006, 82:147-153.
27. Lee S.J., Klar N., Weeks J.C., et al. Predicting costs of stem-cell transplantation. J Clin Oncol 2000, 18:64-71.
28. Sedlacek P., Mejstrikova E., Formankova R., et al. Allo-SCT in children with high-risk leukemia using unmanipulated grafts from alternative donors. Bone Marrow Transplant 2008, 42:10-15.
29. Cohn R.J., Goodenough B., Foreman T., et al. Hidden financial costs in treatment for childhood cancer: an Australian study of lifestyle implications for families absorbing out-of-pocket expenses. J Pediatr Hematol Oncol 2003, 25:854-863.
30. Barr R.D., Sala A. Hidden financial costs in the treatment for childhood cancer. J Pediatr Hematol Oncol 2003, 25:842-844.
31. Polinder S., Meerding W.J., van Exel J., et al. Societal discounting of health effects in cost-effectiveness analyses: the influence of life expectancy. Pharmacoeconomics 2005, 23:791-802.
32. Griebsch I., Coast J., Brown J. Quality-adjusted life-years lack quality in pediatric care: a critical review of published cost-utility studies in child health. Pediatrics 2005, 115:e600-e614.
33. Andrykowski M.A., Bishop M.M., Hahn E.A., et al. Long-term health-related quality of life, growth, and spiritual well-being after hematopoietic stem-cell transplantation. J Clin Oncol 2005, 23:599-608.
34. Caocci G., Efficace F., Ciotti F., et al. Prospective assessment of health-related quality of life in pediatric beta-thalassemia patients following hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2010, 17:861-866.
35. Worel N., Biener D., Kalhs P., et al. Long-term outcome and quality of life of patients who are alive and in complete remission more than two years after allogeneic and syngeneic stem cell transplantation. Bone Marrow Transplant 2002, 30:619-626.
36. Haller M., Gutjahr G., Kramar R., et al. Cost-effectiveness analysis of renal replacement therapy in Austria. Nephrol Dial Transplant 2011, 26:2988-2995.
37. Greving J.P., Visseren F.L., de Wit G.A., et al. Statin treatment for primary prevention of vascular disease: whom to treat? Cost-effectiveness analysis. BMJ 2011, 342:d1672.
38. Eichler H.G., Kong S.X., Gerth W.C., et al. Use of cost-effectiveness analysis in health-care resource allocation decision-making: how are cost-effectiveness thresholds expected to emerge?. Value Health 2004, 7:518-528.
39. Devlin N., Parkin D. Does NICE have a cost-effectiveness threshold and what other factors influence its decisions? A binary choice analysis. Health Econ 2004, 13:437-452.
40. Rascati K.L. The $64,000 question: what is a quality-adjusted life-year worth?. Clin Ther 2006, 28:1042-1043.